These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10783517)

  • 1. Photochemical and chemical oxidation of mexiletine and tocainide. Structure elucidation of the major products.
    Takács M; Vámos J; Tóth G; Mikó-Hideg Z
    Arch Pharm (Weinheim); 2000 Mar; 333(2-3):48-52. PubMed ID: 10783517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between negative inotropic and chronotropic effects of tocainide and five class I antiarrhythmic drugs in the coronary perfused guinea-pig heart.
    Matsumoto T; Hasegawa J; Mashiba H
    Gen Pharmacol; 1993 May; 24(3):599-604. PubMed ID: 8365639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2D- and 3D-QSAR of tocainide and mexiletine analogues acting as Na(v)1.4 channel blockers.
    Carrieri A; Muraglia M; Corbo F; Pacifico C
    Eur J Med Chem; 2009 Apr; 44(4):1477-85. PubMed ID: 19027197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination of sotalol with the class I B substances mexiletine or tocainide in complex ventricular extrasystole].
    Wagner WL; Manz M; Lüderitz B
    Z Kardiol; 1987 May; 76(5):296-302. PubMed ID: 2441535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide.
    Wei X; Dai R; Zhai S; Thummel KE; Friedman FK; Vestal RE
    J Pharmacol Exp Ther; 1999 May; 289(2):853-8. PubMed ID: 10215663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class IB antiarrhythmic drugs: tocainide, mexiletine, and moricizine.
    Snyder DW
    J La State Med Soc; 1989 May; 141(5):21-5. PubMed ID: 2499645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.
    Denaro CP; Benowitz NL
    Med Toxicol Adverse Drug Exp; 1989; 4(6):412-28. PubMed ID: 2513464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of class Ib (lidocaine-like) antiarrhythmic agents for prevention of sustained ventricular tachycardia secondary to coronary artery disease.
    Reiter MJ; Easley AR; Mann DE
    Am J Cardiol; 1987 Jun; 59(15):1319-24. PubMed ID: 3109228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologation of mexiletine alkyl chain and stereoselective blockade of skeletal muscle sodium channels.
    Duranti A; Franchini C; Lentini G; Loiodice F; Tortorella V; De Luca A; Pierno S; Conte Camerino D
    Eur J Med Chem; 2000 Jan; 35(1):147-56. PubMed ID: 10733611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide.
    De Luca A; Natuzzi F; Falcone G; Duranti A; Lentini G; Franchini C; Tortorella V; Camerino DC
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Dec; 356(6):777-87. PubMed ID: 9453464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of antiarrhythmic drugs.
    Lüderitz B; Mletzko R; Jung W; Manz M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S48-52. PubMed ID: 1723119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative potency of mexiletine, lidocaine, and tocainide as inhibitors of rat liver CYP1A1 activity.
    Wei X; Loi CM; Jarvi EJ; Vestal RE
    Drug Metab Dispos; 1995 Dec; 23(12):1335-8. PubMed ID: 8689940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antifibrillatory potency of aprindine, mexiletine, tocainide and lignocaine compared on Langendorff-perfused hearts of rabbits and guinea-pigs.
    Almotrefi AA; Baker JB
    J Pharm Pharmacol; 1980 Nov; 32(11):746-50. PubMed ID: 6110721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels.
    De Luca A; Natuzzi F; Desaphy JF; Loni G; Lentini G; Franchini C; Tortorella V; Camerino DC
    Mol Pharmacol; 2000 Feb; 57(2):268-77. PubMed ID: 10648636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mexiletine and tocainide: does response to one predict response to the other?
    Hession M; Blum R; Podrid PJ; Lampert S; Stein J; Lown B
    J Am Coll Cardiol; 1986 Feb; 7(2):338-43. PubMed ID: 3080508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversed-phase LC resolutions of chiral antiarrhythmic agents via derivatization with homochiral isothiocyanates.
    Gal J; Desai DM; Meyer-Lehnert S
    Chirality; 1990; 2(1):43-51. PubMed ID: 2119207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use-dependent blocking action of newly developed lidocaine-analogs on maximum rate of rise of action potentials in guinea pig papillary muscle.
    Toyama J; Kodama I; Kusunoki T; Ishihara T; Hattori Y; Yamada K
    Jpn Heart J; 1987 Mar; 28(2):273-85. PubMed ID: 3110457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interactions of quinidine and propranolol with mexiletine, encainide, flecainide and tocainide].
    Halawa B
    Pol Tyg Lek; 1990 Mar 5-12; 45(10-11):222-4. PubMed ID: 2120685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis for the antigenicity of lidocaine analogs: tocainide and mexiletine.
    Duff HJ; Roden DM; Marney S; Colley DG; Maffucci R; Primm RK; Oates JA; Woosley RL
    Am Heart J; 1984 Mar; 107(3):585-9. PubMed ID: 6421133
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.